Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
It plans to deliver over 300 million doses to the Indian government
Subscribe To Our Newsletter & Stay Updated
